Tyra Biosciences Reports Q1 Loss and Cash Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Source: seekingalpha
- Financial Performance: Tyra Biosciences reported a GAAP EPS of -$0.64 for Q1 2026, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Reserves: As of March 31, 2026, Tyra had $383.5 million in cash, cash equivalents, and short-term investments, which are expected to support the company's operational plans into the second half of 2028, ensuring its continued viability.
- Rising Administrative Expenses: General and administrative expenses for Q1 2026 were $8.5 million, up from $6.9 million in the same period of 2025, primarily driven by increased compensation and personnel costs due to headcount growth, highlighting cost pressures during the company's expansion.
- Widening Net Loss: The net loss for the first quarter was $39.3 million, compared to $28.1 million for the same period in 2025, indicating that the company still faces significant challenges in improving its financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TYRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TYRA
Wall Street analysts forecast TYRA stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.680
Low
30.00
Averages
33.75
High
37.00
Current: 32.680
Low
30.00
Averages
33.75
High
37.00
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HighVista Strategies Increases Stake in Tyra Biosciences
- Stake Increase: On May 15, 2026, HighVista Strategies disclosed the purchase of 96,218 shares of Tyra Biosciences, valued at approximately $3.11 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The value of Tyra's position increased by $4.11 million at quarter-end due to both the additional shares acquired and stock price appreciation, reflecting robust performance and market recognition in the biopharmaceutical sector.
- Stock Performance: As of May 14, 2026, Tyra's shares were priced at $36.51, representing a 280% increase over the past year, significantly outperforming the S&P 500 by 250 percentage points, showcasing investor optimism regarding potential clinical catalysts.
- Financial Position: Tyra ended the first quarter with approximately $383.5 million in cash and cash equivalents, which management indicates should fund operations into the second half of 2028, enhancing its financial stability for upcoming clinical trials.
See More
Tyra Biosciences Reports Q1 Loss and Cash Position
- Financial Performance: Tyra Biosciences reported a GAAP EPS of -$0.64 for Q1 2026, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Reserves: As of March 31, 2026, Tyra had $383.5 million in cash, cash equivalents, and short-term investments, which are expected to support the company's operational plans into the second half of 2028, ensuring its continued viability.
- Rising Administrative Expenses: General and administrative expenses for Q1 2026 were $8.5 million, up from $6.9 million in the same period of 2025, primarily driven by increased compensation and personnel costs due to headcount growth, highlighting cost pressures during the company's expansion.
- Widening Net Loss: The net loss for the first quarter was $39.3 million, compared to $28.1 million for the same period in 2025, indicating that the company still faces significant challenges in improving its financial health.
See More
Boone Capital Acquires New Stake in Tyra Biosciences
- New Investment Disclosure: On February 17, 2026, Boone Capital Management disclosed its position in Tyra Biosciences, acquiring 398,482 shares worth $10.48 million, reflecting confidence in the company's growth potential.
- Asset Management Proportion: The newly acquired shares represent 3.3% of Boone Capital's 13F reportable AUM as of December 31, 2025, indicating the firm's significant focus on Tyra within its investment portfolio.
- Stock Performance: As of last Friday, Tyra's shares were priced at $38.67, having surged 253% over the past year, significantly outperforming the S&P 500's 16% increase during the same period, showcasing strong market optimism.
- Financial Status Analysis: Despite a net loss nearing $120 million over the past year, Tyra maintains approximately $256 million in cash and investments, sufficient to fund operations into 2027, highlighting its ongoing development potential in the biotech sector.
See More
Boone Capital Acquires 398,482 Shares of Tyra Biosciences
- New Investment Disclosure: Boone Capital disclosed the acquisition of 398,482 shares of Tyra Biosciences in Q4 2026, totaling $10.48 million, indicating a strategic interest in the biotech sector despite this position not being among the fund's top five holdings.
- Financial Condition Analysis: Tyra Biosciences focuses on precision therapies for cancer and rare diseases, and while the company reported a net loss of approximately $120 million for the year, its $256 million in cash and investments is sufficient to fund operations into 2027, showcasing financial stability.
- Clinical Strategy Focus: Tyra is narrowing its focus around a defined clinical strategy with three Phase 2 programs targeting FGFR3 biology, demonstrating discipline and foresight in the biotech field despite facing significant losses.
- Market Performance Review: Since the end of last quarter, Tyra's shares have climbed about 47%, suggesting Boone Capital's investment may have already paid off, although the analyst team did not include Tyra in their current list of top investment stocks.
See More
Tyra Biosciences Q4 Earnings Report Analysis
- Disappointing Earnings: Tyra Biosciences reported a Q4 GAAP EPS of -$0.57, missing expectations by $0.04, indicating ongoing challenges in profitability that could undermine investor confidence.
- Net Loss Reported: The company recorded a net loss of $33.8 million, reflecting high costs in R&D and operations, which may lead to increased future financing needs and impact shareholder returns.
- Cash Position: As of the end of the reporting period, Tyra Biosciences held $256 million in cash, cash equivalents, and marketable securities, providing a solid liquidity position, yet ongoing losses may restrict future investment and expansion capabilities.
- Market Reaction Outlook: Given the earnings miss, investors may adopt a cautious stance towards Tyra Biosciences' future performance, potentially leading to stock price volatility and a decline in market confidence.
See More
Tyra Biosciences Launches 'Dabogratinib 3x3' Strategy for Blockbuster Indications
- New Strategy Launch: Tyra Biosciences has unveiled its 'dabogratinib 3x3' strategy, aiming to conduct three late-stage clinical studies in low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and achondroplasia (ACH), demonstrating the company's strategic focus in precision medicine.
- Clinical Data Progress: Interim Phase 2 data readouts for SURF302 are expected by the end of 1H 2026, with BEACH301 scheduled for 2H 2026, indicating Tyra's proactive advancement in clinical trials that may lay the groundwork for future regulatory submissions.
- Strong Financial Position: As of Q4 2025, Tyra reported cash, cash equivalents, and marketable securities totaling $256 million, providing a runway through at least 2027, showcasing its financial resilience in supporting R&D and market expansion.
- Significant Market Potential: By focusing on selective FGFR3 inhibition, Tyra aims to address high unmet medical needs while creating substantial long-term value, underscoring its strategic importance and competitive edge in the biotechnology sector.
See More
HighVista Strategies Increases Stake in Tyra Biosciences
- Stake Increase: On May 15, 2026, HighVista Strategies disclosed the purchase of 96,218 shares of Tyra Biosciences, valued at approximately $3.11 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The value of Tyra's position increased by $4.11 million at quarter-end due to both the additional shares acquired and stock price appreciation, reflecting robust performance and market recognition in the biopharmaceutical sector.
- Stock Performance: As of May 14, 2026, Tyra's shares were priced at $36.51, representing a 280% increase over the past year, significantly outperforming the S&P 500 by 250 percentage points, showcasing investor optimism regarding potential clinical catalysts.
- Financial Position: Tyra ended the first quarter with approximately $383.5 million in cash and cash equivalents, which management indicates should fund operations into the second half of 2028, enhancing its financial stability for upcoming clinical trials.
See More
Tyra Biosciences Reports Q1 Loss and Cash Position
- Financial Performance: Tyra Biosciences reported a GAAP EPS of -$0.64 for Q1 2026, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Reserves: As of March 31, 2026, Tyra had $383.5 million in cash, cash equivalents, and short-term investments, which are expected to support the company's operational plans into the second half of 2028, ensuring its continued viability.
- Rising Administrative Expenses: General and administrative expenses for Q1 2026 were $8.5 million, up from $6.9 million in the same period of 2025, primarily driven by increased compensation and personnel costs due to headcount growth, highlighting cost pressures during the company's expansion.
- Widening Net Loss: The net loss for the first quarter was $39.3 million, compared to $28.1 million for the same period in 2025, indicating that the company still faces significant challenges in improving its financial health.
See More
Boone Capital Acquires New Stake in Tyra Biosciences
- New Investment Disclosure: On February 17, 2026, Boone Capital Management disclosed its position in Tyra Biosciences, acquiring 398,482 shares worth $10.48 million, reflecting confidence in the company's growth potential.
- Asset Management Proportion: The newly acquired shares represent 3.3% of Boone Capital's 13F reportable AUM as of December 31, 2025, indicating the firm's significant focus on Tyra within its investment portfolio.
- Stock Performance: As of last Friday, Tyra's shares were priced at $38.67, having surged 253% over the past year, significantly outperforming the S&P 500's 16% increase during the same period, showcasing strong market optimism.
- Financial Status Analysis: Despite a net loss nearing $120 million over the past year, Tyra maintains approximately $256 million in cash and investments, sufficient to fund operations into 2027, highlighting its ongoing development potential in the biotech sector.
See More
Boone Capital Acquires 398,482 Shares of Tyra Biosciences
- New Investment Disclosure: Boone Capital disclosed the acquisition of 398,482 shares of Tyra Biosciences in Q4 2026, totaling $10.48 million, indicating a strategic interest in the biotech sector despite this position not being among the fund's top five holdings.
- Financial Condition Analysis: Tyra Biosciences focuses on precision therapies for cancer and rare diseases, and while the company reported a net loss of approximately $120 million for the year, its $256 million in cash and investments is sufficient to fund operations into 2027, showcasing financial stability.
- Clinical Strategy Focus: Tyra is narrowing its focus around a defined clinical strategy with three Phase 2 programs targeting FGFR3 biology, demonstrating discipline and foresight in the biotech field despite facing significant losses.
- Market Performance Review: Since the end of last quarter, Tyra's shares have climbed about 47%, suggesting Boone Capital's investment may have already paid off, although the analyst team did not include Tyra in their current list of top investment stocks.
See More
Tyra Biosciences Q4 Earnings Report Analysis
- Disappointing Earnings: Tyra Biosciences reported a Q4 GAAP EPS of -$0.57, missing expectations by $0.04, indicating ongoing challenges in profitability that could undermine investor confidence.
- Net Loss Reported: The company recorded a net loss of $33.8 million, reflecting high costs in R&D and operations, which may lead to increased future financing needs and impact shareholder returns.
- Cash Position: As of the end of the reporting period, Tyra Biosciences held $256 million in cash, cash equivalents, and marketable securities, providing a solid liquidity position, yet ongoing losses may restrict future investment and expansion capabilities.
- Market Reaction Outlook: Given the earnings miss, investors may adopt a cautious stance towards Tyra Biosciences' future performance, potentially leading to stock price volatility and a decline in market confidence.
See More
Tyra Biosciences Launches 'Dabogratinib 3x3' Strategy for Blockbuster Indications
- New Strategy Launch: Tyra Biosciences has unveiled its 'dabogratinib 3x3' strategy, aiming to conduct three late-stage clinical studies in low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and achondroplasia (ACH), demonstrating the company's strategic focus in precision medicine.
- Clinical Data Progress: Interim Phase 2 data readouts for SURF302 are expected by the end of 1H 2026, with BEACH301 scheduled for 2H 2026, indicating Tyra's proactive advancement in clinical trials that may lay the groundwork for future regulatory submissions.
- Strong Financial Position: As of Q4 2025, Tyra reported cash, cash equivalents, and marketable securities totaling $256 million, providing a runway through at least 2027, showcasing its financial resilience in supporting R&D and market expansion.
- Significant Market Potential: By focusing on selective FGFR3 inhibition, Tyra aims to address high unmet medical needs while creating substantial long-term value, underscoring its strategic importance and competitive edge in the biotechnology sector.
See More
